Enfortumab vedotin (EV) as monotherapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of stage I of a phase 2 trial.
| Autor: | Swami, Umang, Maughan, Benjamin L., Boucher, Kenneth M., Nordblad, Blake, Lloyd, Jennifer, Batten, Julia, Phunrab, Tenzin Kunsang, Quertinmont, Joshua, Kohli, Manish, Gupta, Sumati, Agarwal, Neeraj |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p152-152, 235p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|